New Abingworth fund beats expectations


Lifesciences investment group Abingworth Bioventures has closed its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. The fund — Abingworth’s 12th invested in companies in Europe and the U.S. —  exceeded its target of $300 million.  The firm has more than $1.2 billion under management.

The fund invests broadly across all stages of development, including early and late-stage venture deals, clinical co-development, venture investments in public equities (VIPEs) and public equities. Investment size per company will typically range from $15 million to $30 million.

Its medtech portfolio ranges from California permanent-contraception maker Adiana to Stanmore Implants, a UK orthopedics company.

Get the full story on our sister site, Mass Device.

DeviceTalks Boston 2018 is Bigger and Better than ever!

textadimage Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.

DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.

Early Registration is now open.

Speak Your Mind